By making lung cancer screening available to a larger population, the new guideline from the U.S. Preventive Services Task Force could save an additional 120 lives per 100,000 Americans, said Michael J. Barry, a member of the Task Force, and a professor of medicine at Harvard Medical School.
Richard Pazdur, FDA’s top oncologist who last week received a battlefield promotion to the role of director of the FDA Center for Drug Evaluation and Research, is described as a stabilizing figure respected by major patient groups, oncology professional societies, and the industry.
